NurExone Launches Licensing Efforts for ExoTherapy Platform
14 févr. 2024 16h20 HE
|
NurExone Biologic Inc
NurExone Biologic launches licensing efforts for its ExoTherapy platform for creating nanodrugs by loading therapeutic molecular cargo into exosomes.
Nurexone Biologic Initiates European Orphan Drug Designation Process Following U.S. Grant
02 févr. 2024 16h05 HE
|
NurExone Biologic Inc
Nurexone Biologic Initiates European Orphan Drug Designation Process Following U.S. Grant for its groundbreaking ExoPTEN product
ELEVAI Labs Inc. Announces Issuance of Patent from U.S. Patent & Trademark Office
24 janv. 2024 08h30 HE
|
Elevai Labs Inc.
ELEVAI Labs Inc. Announces Issuance of Patent from U.S. Patent & Trademark Office
ELEVAI LABS, Inc. Reports Strong Preliminary Unaudited Financial Performance for Fiscal Year 2023, Highlighting Significant Revenue Growth and Expanding Global Reach
17 janv. 2024 08h30 HE
|
Elevai Labs Inc.
ELEVAI Reports Strong Preliminary Unaudited Financial Performance for Fiscal Year 2023, Highlighting Significant Revenue Growth and Expanding Global Reach
ELEVAI Labs, Inc. Acquires Worldwide License Agreement for Proprietary Stem Cell Manufacturing Technology
16 janv. 2024 08h30 HE
|
Elevai Labs Inc.
ELEVAI Labs, Inc. Acquires Worldwide License Agreement for Proprietary Stem Cell Manufacturing Technology
NurExone Announces Closing of a Private Placement for Gross Proceeds of Approximately CAD$2 Million
05 janv. 2024 08h30 HE
|
NurExone Biologic Inc
NurExone Announces Closing of a Private Placement for Gross Proceeds of Approximately CAD$2 Million
ELEVAI LABS, Inc. to Participate in Upcoming Aesthetic Industry Conferences
02 janv. 2024 09h15 HE
|
Elevai Labs Inc.
ELEVAI LABS, Inc. to Participate in Upcoming Aesthetic Industry Conferences
Elevai Labs Inc Announces Financial Results for the Quarter Ended September 30, 2023
11 déc. 2023 09h15 HE
|
Elevai Labs Inc.
Elevai Labs Inc Announces Financial Results for the Quarter Ended September 30, 2023
NurExone Biologic Extends Spinal Cord Injury Therapy Portfolio With New RNA Sequences Promoting Healing and Regeneration
29 nov. 2023 08h30 HE
|
NurExone Biologic Inc
NurExone Biologic expands its portfolio of products to address spinal cord injuries & neuron regeneration in CNS indications
NurExone Biologic to Present Exosome-Based Therapy for Spinal Cord Injury in Regenerative Medicine Session at Upcoming Extracellular Vesicles Forum
05 oct. 2023 08h30 HE
|
NurExone Biologic Inc
NurExone Biologic will present at the EVs Forum in Cambridge presents advances in exosome therapy for spinal cord injuries, highlighting ExoPTEN potential